[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-436858-105":59,"doc-detail-436858-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","understanding-gastric-adenosquamous-cell-carcinoma-insights-from-immunoprofiling","Understanding gastric adenosquamous cell carcinoma - Insights from immunoprofiling","","Gastric adenosquamous cell carcinoma (GASC) is a rare, aggressive digestive tract tumor subtype with distinct clinicopathological patterns and outcomes compared with adenocarcinoma. Editorial synthesis reviews registry and study findings on tumor location and differentiation, emphasizing that a squamous component correlates with poor prognosis. A highlighted retrospective study analyzes treatment results and immunoprofiling biomarkers, including dMMR, CPS, and PD-L1, suggesting implications for frontline immunotherapy and the need for further molecular characterization.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/understanding-gastric-adenosquamous-cell-carcinoma-insights-from-immunoprofiling/436858/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/understanding-gastric-adenosquamous-cell-carcinoma-insights-from-immunoprofiling/436858.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes gastric adenosquamous cell carcinoma clinically aggressive?","Question",{"text":112,"@type":113},"GASC is described as rare with aggressive tumor behavior and a tendency toward poor differentiation. The presence of a squamous component is linked to worse prognosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biomarkers were discussed as relevant in GASC immunoprofiling?",{"text":117,"@type":113},"The text highlights deficient mismatch repair (dMMR) protein, combined positive score (CPS) thresholds, and PD-L1 expression, including an association between PD-L1 ≥5% and better overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the article relate immunotherapy to frontline treatment in GASC?",{"text":121,"@type":113},"Findings from stage IV cases treated with frontline immunotherapy are presented alongside biomarker signals suggesting better responses. The editorial concludes that immunotherapy may be important in management and warrants further study.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},436858,1790989127,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81,"preview_page_count":4},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","J Chin MedAssoc  \nEditorial  \nUnderstanding gastric adenosquamous cell carcinoma: Insights from immunoprofiling  \nChun-Yu Liu*  \nSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, and Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC  \nGastric adenosquamous cell carcinoma (GASC), like other adenosquamous cell carcinomas of the digestive system, is a rare histological subtype with aggressive tumor behavior.1 Recent literature has focused on characterizing the clinicopathological features and distinct clinical outcomes compared to its adenocarcinoma counterpart. While some studies have reported the lower third of the stomach as the most common site for adenosquamous cell carcinoma,2,3 larger registry database studies have reported a higher frequency in the gastric cardia (upper third) .4,5 Poor differentiation is a common tendency,4–6 and the presence of a squamous component appears to contribute to a poor prognosis.7  \nIn the study titled “Immunoprofile of adenosquamous carcinoma in gastric cancer,” Wu et al8 investigated the clinical features, treatment outcomes, and immunoprofile of GASC to determine the optimal treatment modality for these patients. The authors retrospectively reviewed patients with GASC from a single institute and analyzed their clinical data and tumor samples. The study found that the median tumor size in stage III GASC patients was 6.8 cm, and all of these patients underwent radical gastrectomy followed by adjuvant therapy. The median progression-free survival (PFS) and overall survival (OS) for stage III GASC patients were 6.0 and 11.5 months, respectively. Two patients with stage IV GASC received frontline immunotherapy, with a median PFS and OS of 9.0 and 12.5 months, respectively. Immunoprofiling of the GASC samples revealed that 25% of the samples had deficient mismatch repair (dMMR) protein, 75% had a combined positive score (CPS) of ≥1, and 33.3% had a CPS of ≥10. The study also found that programmed death-ligand 1 expression of ≥5% was significantly associated with superior OS. One stage IV patient with CPS ≥10 and dMMR proteins received nivolumab monotherapy as frontline treatment, resulting in a PFS of 14 months. The study suggests that patients with GASC are more likely to exhibit positive results for CPS and dMMR. It highlights the importance of examining biomarkers  \n*Address correspondence. Dr Chun-Yu Liu, Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan, [ROC. E-mail address: cyliu3@vghtpe.gov.tw](ROC. E-mail address: cyliu3@vghtpe.gov.tw) (C.-Y. Liu). Conflicts of interest: Dr. Chun-Yu Liu, an editorial board member at Journal of the Chinese Medical Association, had no role in the peer review process of or decision to publish this article.  \nJournal of Chinese Medical Association. (2023) 86: 780.  \nReceived June 29, 2023; accepted July 18, 2023.  \ndoi: 10. 1097/JCMA.0000000000000967.  \nCopyright © 2023, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)[ ](http://creativecommons.org/licenses/)[by-nc-nd/4.0/](by-nc-nd/4.0/))  \nand considering immunotherapy as frontline systemic treatment for GASC.8  \nThe molecular pathogenesis of GASC is poorly understood. In 2000, Woo et al9 studied microsatellite instability (MSI) caused by defective DNA mismatch repair (MMR) in gastric carcinomas with squamous differentiation. Among the 17 cases, two (12%) demonstrated high-level MSI (MSI-H) at the examined loci. These tumors also exhibited frame-shift mutations at mononucleotide repeats in specific genes targeted by MSI, including TGFBR2, IGF2R, BAX, and MSH6 . Interestingly, mutations within the E2F4 gene were found only in the squamous cell carcinoma portions of the tumors, not in the adenocarcinomat","cbCaifPgVQPD5YjP","https://ap.wps.com/l/cbCaifPgVQPD5YjP","pdf",285183,"English","# Editorial\n## Key clinical and pathologic features of GASC\n## Evidence from retrospective immunoprofiling study\n## Biomarkers and implications for immunotherapy\n## Molecular mechanisms, including MSI and MMR","[{\"question\":\"What makes gastric adenosquamous cell carcinoma clinically aggressive?\",\"answer\":\"GASC is described as rare with aggressive tumor behavior and a tendency toward poor differentiation. The presence of a squamous component is linked to worse prognosis.\"},{\"question\":\"Which biomarkers were discussed as relevant in GASC immunoprofiling?\",\"answer\":\"The text highlights deficient mismatch repair (dMMR) protein, combined positive score (CPS) thresholds, and PD-L1 expression, including an association between PD-L1 ≥5% and better overall survival.\"},{\"question\":\"How does the article relate immunotherapy to frontline treatment in GASC?\",\"answer\":\"Findings from stage IV cases treated with frontline immunotherapy are presented alongside biomarker signals suggesting better responses. The editorial concludes that immunotherapy may be important in management and warrants further study.\"}]","Understanding gastric adenosquamous cell carcinoma - Insights from immunoprofiling | PDF",1790679247]